Method for producing endo-9-azabicyclo[3.3.1]nonan-3-ol derivative

US2016200726A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016200726-A1
Application numberUS-201414913736-A
CountryUS
Kind codeA1
Filing dateAug 14, 2014
Priority dateSep 6, 2013
Publication dateJul 14, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A 9-azabicyclo[3.3.1]nonan-3-one derivative is reacted with a hydrogen in the presence of a catalyst composed of a ruthenium complex to obtain, at a low cost, an endo-9-azabicyclo[3.3.1]nonan-3-ol derivative useful as a production intermediate for agrochemical agents or medicines.

First claim

Opening claim text (preview).

1 . A method for producing a compound represented by formula (II), comprising reacting a compound represented by formula (I) with a hydrogen in a presence of a catalyst consisting of a ruthenium complex: in the formulae (I) and (II), R represents a hydrogen atom, an unsubstituted or substituted alkyl group, an unsubstituted or substituted aralkyl group, or an unsubstituted or substituted alkoxycarbonyl group. 2 . The method according to claim 1 , wherein the ruthenium complex is a compound represented by the following formula: Ru(X)(Y)(Px) n (L) or Ru(X)(Y)(PN) 2 , in the formulae, X and Y each independently represents an anionic ligand, Px represents a phosphine ligand, n represents 1 or 2, L represents a ligand represented by the following formula (III) or a diamine ligand, and PN represents a ligand represented by the following formula (IV): in the formulae, R 1 and R 2 each independently represents a hydrogen atom, an unsubstituted or substituted alkyl group, an unsubstituted or substituted aryl group, or an unsubstituted or substituted aralkyl group, a ring B represents an unsubstituted or substituted hetero ring, a double line portion consisting of a continuous line and a dotted line represents a single bond or a double bond, Z represents a coordinating atom selected from the group consisting of N, P, O, and S, R 3 and R 4 each independently represents an unsubstituted or substituted alkyl group, an unsubstituted or substituted aryl group, or an unsubstituted or substituted aralkyl group, and A represents an unsubstituted or substituted C1 to 4 alkylene group. 3 . The method according to claim 2 , wherein the ruthenium complex is a compound represented by the formula: Ru(X)(Y)(Px) n (L), and L represents a pyridin-2-yl methanamine, a (1-methyl-1H-benzimidazol-2-yl)methanamine, a (5-methylpyrazin-2-yl) methanamine, a benzoxazol-2-yl methanamine, a pyrimidin-2-yl methanamine, a thiazol-2-yl methanamine, or a (pyrazin-2-yl)methanamine. 4 . The method according to claim 2 , wherein the ruthenium complex is a compound represented by the formula: Ru(X)(Y)(Px) n (L), and L represents a diamine ligand represented by the following formula (VI); wherein, R 5 to R 12 each independently represents a hydrogen atom, an unsubstituted or substituted alkyl group, an unsubstituted or substituted aryl group, or an unsubstituted or substituted aralkyl group, two of R 5 to R 12 may be bonded together to from a ring, D represents a single bond, an unsubstituted or substituted alkylene group, an unsubstituted or substituted cycloalkylene group, an unsubstituted or substituted arylene group, or an unsubstituted or substituted divalent hetero ring group. 5 . The method according to claim 2 , wherein the ruthenium complex is a compound represented by the formula: Ru(X)(Y)(PN) 2 , and PN represents a ligand represented by the following formula (V): 6 . The method according to claim 1 , wherein, in the formulae (I) and (II), R represents an unsubstituted or substituted aralkyl group, and the unsubstituted or substituted aralkyl group is a benzyl group.

Assignees

Inventors

Classifications

  • C07D471/08Primary

    Bridged systems · CPC title

  • containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof · CPC title

  • with hydrogen or hydrogen-containing gases · CPC title

  • and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring · CPC title

  • with more than one complexing phosphine-P atom · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016200726A1 cover?
A 9-azabicyclo[3.3.1]nonan-3-one derivative is reacted with a hydrogen in the presence of a catalyst composed of a ruthenium complex to obtain, at a low cost, an endo-9-azabicyclo[3.3.1]nonan-3-ol derivative useful as a production intermediate for agrochemical agents or medicines.
Who is the assignee on this patent?
Nippon Soda Co
What technology area does this patent fall under?
Primary CPC classification C07D471/08. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Jul 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).